UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2016
Commission File Number: 001-36596
TRILLIUM THERAPEUTICS INC.
(Translation of registrant's name into English)
2488 Dunwin Drive
Mississauga, ON, L5L 1J9
Canada
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ ] Form 40-F [X]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)[ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)[ ]
DOCUMENTS FILED AS PART OF THIS FORM 6-K
See the Exhibit Index hereto.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Trillium Therapeutics Inc. | |
Date: November 3, 2016 | |
By: /s/ James Parsons | |
Name: James Parsons | |
Title: Chief Financial Officer |
2
EXHIBIT INDEX
Exhibit | Description |
99.1 | News Release dated November 3, 2016 |
FOR IMMEDIATE RELEASE | NASDAQ: TRIL |
TSX: TR |
TRILLIUM THERAPEUTICS ANNOUNCES INVESTOR AND SCIENTIFIC
PRESENTATION
SCHEDULE FOR REMAINDER OF 2016
TORONTO, Nov. 3, 2016 Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is scheduled to present an update on the companys programs and progress at several upcoming conferences in 2016.
Investor Conference:
| Oppenheimer Life Sciences Summit |
Attendee: Niclas Stiernholm, PhD, Trillium Chief Executive Officer | |
Date and Time: Nov. 29, 2016 | |
Location: Sofitel Hotel, New York City |
Scientific Conferences:
| The Society for Immunotherapy of Cancer (SITC) 31st Annual Meeting |
Presenter: Lisa Johnson, PhD, Trillium Research Scientist | |
Title: CD47 is Overexpressed on Merkel Cell Carcinoma and a Target for SIRPαFc Therapy | |
Date and Time: Nov. 11, 2016, 12:15 - 1:30 p.m. and 6:15 - 7:30 p.m. ET | |
Location: Gaylord National Hotel & Convention Center, National Harbor, MD |
| American Society of Hematology (ASH) 58th Annual Meeting |
Presenter: Stephen Ansell, MD, Division of Hematology, Mayo Clinic | |
Title: A Phase 1 Study of TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47, in | |
Patients with Relapsed or Refractory Hematologic Malignancies | |
Session Name: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma - Clinical Studies: Poster I | |
Date and Time: Dec. 3, 2016, 5:30 - 7:30 p.m. PT | |
Location: San Diego Convention Center, Hall GH, San Diego |
1
Presenter: Zezhou Wang, PhD, Trillium Research Scientist | |
Title: TTI-281, an Orally Bioavailable Bromodomain and Extraterminal Domain (BET) | |
Inhibitor, Is a Promising Candidate for the Treatment of Multiple Myeloma | |
Session Name: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: | |
Poster I | |
Date and Time: Dec. 3, 2016, 5:30 - 7:30 p.m. PT | |
Location: San Diego Convention Center, Hall GH, San Diego | |
Presenter: Jaehyun Choi, PhD, Trillium Research Scientist | |
Title: Preclinical Characterization of TTI-281, a Novel, Orally Bioavailable BET Inhibitor: | |
Predictive Biomarker Identification and Combination Treatment Analysis | |
Session Name: 802. Chemical Biology and Experimental Therapeutics: Poster III | |
Date and Time: Dec. 5, 2016, 6:00 - 8:00 p.m. PT | |
Location: San Diego Convention Center, Hall GH, San Diego |
About Trillium Therapeutics
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The companys lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (do not eat) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (eat) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing in advanced hematologic malignancies, and a second Phase 1 trial is underway in solid tumors (NCT02890368). Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the companys most advanced preclinical program is an orally-available bromodomain inhibitor, followed by an epidermal growth factor receptor antagonist with increased uptake in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase.
For more information visit: www.trilliumtherapeutics.com
Caution Regarding Forward-Looking Information
This press release may contain forward-looking statements, which reflect Trilliums current expectation regarding future results, events or developments. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties are described in the companys ongoing quarterly and annual reporting. Except as required by applicable securities laws, Trillium undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.
Company Contact:
James Parsons
Chief Financial
Officer
Trillium Therapeutics Inc.
2
416-595-0627 x232
james@trilliumtherapeutics.com
www.trilliumtherapeutics.com
Investor and Media Relations:
Mark Corbae
Canale
Communications for Trillium Therapeutics
619-849-5375
mark@canalecomm.com